Targeting USP33 in multiple sclerosis.
This project started with a disease question: what molecular signals could help explain demyelination in MS, and could one of those signals become a therapeutic target? The page follows the work from gene expression analysis to the RNAi hypothesis.
USP33 came out of a broader search, not a pre-picked story.
The first phase used GEO2R on brain-tissue samples from 10 controls and 40 MS patients. Genes were filtered using statistical significance and fold-change, then interpreted through pathway and network tools.
USP33
Selected focal gene because it was significantly overexpressed and connected to ubiquitin-mediated proteolysis.
The biological idea is about protein regulation becoming part of demyelination.
Multiple sclerosis damages the myelin sheath around neurons. This project connects that clinical phenotype to a molecular path: USP33 overexpression, ubiquitin-mediated proteolysis, and potential degradation of myelin-related proteins such as MBP and PLPs.
USP33 is overexpressed in MS samples.
The MS brain-tissue analysis showed USP33 with p = 1.49E-08 and logFC = 0.97364. The hypothesis is that dysregulated deubiquitination contributes to immune activation and demyelination.
The therapeutic direction was RNAi: reduce USP33 expression instead of just describing it.
After identifying USP33, the next step was asking whether its expression could be intentionally downregulated. The poster moves through UCSC, ENCODE, JASPAR, and miRBase to connect gene location, regulatory structure, and RNAi feasibility.
miRBase
The miRNA/siRNA search supported the RNAi idea: use targeted RNA interference to reduce USP33 expression at the mRNA level.
The page should make the ambition clear, but also show where the evidence still needs to grow.
What worked
The analysis connected a significantly dysregulated gene to a biologically meaningful pathway. KEGG identified ubiquitin-mediated proteolysis with FDR 2.61E-06, and STRING-DB added network context around USP33.
What to be careful about
The sample classes were imbalanced: 10 controls versus 40 MS samples. That means the USP33 signal is promising, but it should be treated as a hypothesis that needs validation rather than a completed therapeutic claim.
Next experiments
The next step is prospective validation: testing whether reducing USP33 changes MS-relevant biology. The poster points toward cDNA synthesis, IHC on MS brain samples, and drug-screening assays as the bridge from bioinformatics signal to experimental evidence.